Jill Murphy is an associate editor for Pharmacy Times®. She graduated from Monmouth University in 2018 in communication and was previously a copywriter and communications specialist at a marketing agency prior to her start at the publication.
Study Shows Cancer Patients Overlooked in COVID-19 Vaccine Rollout
January 3rd 2022The study authors sought to determine the proportion of states that elected to follow CDC recommendations by identifying each state’s COVID-19 vaccination webpage through keyword-based internet search and set out to identify information about vaccinations for patients with cancer.
Read More
Link Is Seen to Commonly Screened Protein During Pregnancy
December 22nd 2021The data highlight a new role for pregnancy-associated plasma protein A, known as PAPP-A, in gestational diabetes, with translational potential as both a diagnostic tool and therapeutic target, according to the investigators.
Read More
Study: Immune-Boosting Antibody Treatment Isatuximab Meets Primary Endpoint for Multiple Myeloma
December 15th 2021This trial is the first to assess the use of isatuximab as a first-line treatment for newly diagnosed, transplant-eligible patients up to 70 years of age, according to the study authors.
Read More
Acalabrutinib Shows Significant Survival Benefit in Patients With Chronic Lymphocytic Leukemia
December 12th 2021The multicenter phase 3 study randomized patients with R/R CLL 1:1 to receive acalabrutinib 100 mg orally twice daily or investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab until disease progression or unacceptable toxicity.
Read More
Roche’s CINtec PLUS Cytology Test Beneficial for Women at Higher Risk of Developing Cervical Cancer
November 16th 2021In the IMPACT trial, women who were positive for high-risk HPV received a follow-up triage test to help determine whether their cervical cells were transforming to cervical pre-cancer.
Read More
Study Discovers New Way to Increase Efficacy of Antibiotics
November 9th 2021This research could help improve the efficacy of antibiotics without clinicians having to attempt risky strategies such as providing patients with higher doses or relying on the discovery of new types of antibiotics, according to the study authors.
Read More
FDA Accepts BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
November 3rd 2021The FDA also granted Priority Review designation for the toripalimab BLA and set a Prescription Drug User Fee Act action date for April 2022; however, the FDA is not currently planning to hold an advisory committee meeting to discuss the application.
Read More
New Research Confirms High Toxin Levels Linked to More Severe C. Difficile Infection
November 1st 2021The concentration of C. diff toxins in the stool was linked to how sick patients were at the time of diagnosis and was associated with adverse outcomes, including the risk of infection returning after treatment.
Read More